ReviewWorld journal of gastroenterology2008
Liver cell transplantation for Crigler-Najjar syndrome type I: update and perspectives.
Review in World journal of gastroenterology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed.
- Therapeutic Options for Crigler-Najjar Syndrome: A Scoping Review.International journal of molecular sciences · 2024Article
- Type II Crigler-Najjar syndrome: a case report and literature review.Frontiers in medicine · 2024Article
- Cellular Therapies in Pediatric Liver Diseases.Cells · 2022Review
- Update on a previously reported missense mutation: The c.1160 C>A mutation in the UGT1A1 gene result in Crigler-Najjar syndrome type 1.Molecular genetics & genomic medicine · 2021Article
- Hepatocyte organoids and cell transplantation: What the future holds.Experimental & molecular medicine · 2021Review
- Distinct EpCAM-Positive Stem Cell Niches Are Engaged in Chronic and Neoplastic Liver Diseases.Frontiers in medicine · 2020Review
- Hepatocyte Transplantation to the Liver via the Splenic Artery in a Juvenile Large Animal Model.Cell transplantation · 2019Article
- Review
- Article
- Ultrasound-guided in Utero Transplantation of Placental Stem Cells into the Liver of Crigler-Najjar Syndrome Model Rat.Transplantation · 2019Article
- Hepatocyte Transplantation: Quo Vadis?International journal of radiation oncology, biology, physics · 2019Review
- Preclinical Development of an AAV8-hUGT1A1 Vector for the Treatment of Crigler-Najjar Syndrome.Molecular therapy. Methods & clinical development · 2019Article
- Macroporous Dual-compartment Hydrogels for Minimally Invasive Transplantation of Primary Human Hepatocytes.Transplantation · 2018Article
- Cell-based liver therapies: past, present and future.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2018Review
- Hepatocyte transplantation and advancements in alternative cell sources for liver-based regenerative medicine.Journal of molecular medicine (Berlin, Germany) · 2018Review
- Hepatocyte transplantation: past efforts, current technology, and future expansion of therapeutic potential.The Journal of surgical research · 2018Review
- Human hepatocyte transplantation for liver disease: current status and future perspectives.Pediatric research · 2018Review
- Domino Hepatocyte Transplantation: A Therapeutic Alternative for the Treatment of Acute Liver Failure.Canadian journal of gastroenterology & hepatology · 2018Review
- Hepatocyte transplantation: Consider infusion before incision.World journal of transplantation · 2017Review
- Clinical Hepatocyte Transplantation: What Is Next?Current transplantation reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Liver cell transplantation is an attractive technique to treat liver-based inborn errors of metabolism. The feasibility and efficacy of the procedure has been demonstrated, leading to medium term partial metabolic control of various diseases. Crigler-Najjar is the paradigm of such diseases in that the host liver is lacking one function with an otherwise normal parenchyma. The patient is at permanent risk for irreversible brain damage. The goal of liver cell transplantation is to reduce serum bilirubin levels within safe limits and to alleviate phototherapy requirements to improve quality of life. Preliminary data on Gunn rats, the rodent model of the disease, were encouraging and have led to successful clinical trials. Herein we report on two additional patients and describe the current limits of the technique in terms of durability of the response as compared to alternative therapeutic procedures. We discuss the future developments of the technique and new emerging perspectives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.